Kura Oncology Inc. (KURA)
NASDAQ: KURA
· Real-Time Price · USD
9.57
0.43 (4.70%)
At close: Oct 03, 2025, 3:59 PM
9.45
-1.25%
After-hours: Oct 03, 2025, 07:54 PM EDT
4.70% (1D)
| Bid | 8.71 |
| Market Cap | 830.65M |
| Revenue (ttm) | 83.28M |
| Net Income (ttm) | -197.17M |
| EPS (ttm) | -2.33 |
| PE Ratio (ttm) | -4.11 |
| Forward PE | -3.92 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 9.8 |
| Volume | 1,725,234 |
| Avg. Volume (20D) | 1,671,547 |
| Open | 9.25 |
| Previous Close | 9.14 |
| Day's Range | 9.21 - 9.74 |
| 52-Week Range | 5.41 - 19.73 |
| Beta | 0.32 |
| Ex-Dividend Date | n/a |
About KURA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KURA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KURA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsKura Oncology Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+10.72%
Kura Oncology shares are trading higher after the ...
Unlock content with
Pro Subscription
8 months ago
-2.54%
Kura Oncology shares are trading lower. The company announced topline results from KOMET-001.
2 weeks ago · seekingalpha.com
Kura Oncology Transitioning To Commercial Stage: Why I Choose To BuyKura Oncology is rated Buy, driven by a strong cash position, strategic Kyowa Kirin partnership, and a robust, diversified pipeline. KURA's lead asset, Ziftomenib, targets AML and awaits a pivotal FDA...
1 month ago · fool.com
Kura (KURA) Revenue Drops 61%Kura (KURA) Revenue Drops 61%